AstraZeneca plc (AZN) Given “Hold” Rating at Shore Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reissued by investment analysts at Shore Capital in a research note issued to investors on Tuesday.
AZN has been the topic of several other research reports. Goldman Sachs Group Inc lowered their target price on shares of AstraZeneca plc from GBX 4,000 ($52.04) to GBX 3,900 ($50.74) and set a “sell” rating on the stock in a research note on Tuesday, January 24th. Investec initiated coverage on shares of AstraZeneca plc in a research note on Monday, January 23rd. They set a “hold” rating and a GBX 4,600 ($59.84) target price on the stock. HSBC Holdings plc reaffirmed a “hold” rating and set a GBX 4,700 ($61.14) target price on shares of AstraZeneca plc in a research note on Wednesday, January 25th. Jefferies Group LLC lifted their price target on AstraZeneca plc from GBX 5,250 ($68.30) to GBX 5,350 ($69.60) and gave the stock a “buy” rating in a report on Thursday, March 9th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, January 26th. Five analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of GBX 5,041.80 ($65.59).
AstraZeneca plc (LON:AZN) traded up 0.35% during midday trading on Tuesday, reaching GBX 5227.00. 1,566,267 shares of the company were exchanged. The stock’s market capitalization is GBX 66.17 billion. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The firm’s 50 day moving average price is GBX 4,839.40 and its 200-day moving average price is GBX 4,584.95.
COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Given “Hold” Rating at Shore Capital” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/28/astrazeneca-plc-azn-given-hold-rating-at-shore-capital.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.